Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?

We report a young male patient who developed plasma cell myeloma/plasmacytoma 11 years after having received an allogeneic hematopoietic cell transplantation for AML. The patient received a second transplantation from the same donor without immunosuppression and developed graft-versus-host disease (...

Full description

Saved in:
Bibliographic Details
Published inCase Reports in Medicine Vol. 2012; no. 2012; pp. 1 - 3-089
Main Authors Bakanay, Sule Mine, Serbest, Esin, Dalva, Klara, Kuzu, Isinsu, Beksac, Meral
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Limiteds 01.01.2012
Hindawi Puplishing Corporation
Hindawi Publishing Corporation
Wiley
Subjects
Case Report
Online AccessGet full text

Cover

More Information
Summary:We report a young male patient who developed plasma cell myeloma/plasmacytoma 11 years after having received an allogeneic hematopoietic cell transplantation for AML. The patient received a second transplantation from the same donor without immunosuppression and developed graft-versus-host disease (GVHD). Our observation has two aspects that warrant attention: first, insufficiency of long-term tolerance to prevent GVHD in the absence of immunosuppression and second, a stromal or genetic susceptibility to develop hematologic malignancies despite of a complete donor-type chimerism.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Academic Editor: Thomas R. Chauncey
ISSN:1687-9627
1687-9635
DOI:10.1155/2012/319530